amgen looking to expand onyx kyprolis, page-19

Point is peace, investors put much higher value on companies already with recurring and increasing revenues than those that don't, thus the reason why I say AHZ should not be included in your list.

You are using Patry's recent attempted $12.5mill capital raising as an argument for PABs cash-mc position against just a handful of other bios that suit your argument. They all have their own reasons for being at their said marketcaps. Again PAB has great potential to increase its share price and marketcap from here but the road is a long one for them. We're looking at ost likely 2nd half of year for trial commencement with Onyx.